Morgan Stanley Comments On China Biologic Products; Shares Rise

In a research note released Tuesday, Morgan Stanley analyst Bin Li commented on China Biologic Products CBPO.

Li believes the stock price will rise in absolute terms over the next 60 days. The analyst also believes the stock is undervalued due to investors' limited knowledge of the Chinese plasma market, a lack of offshore plasma names and low liquidity.

Shares of the company are up 14 percent Tuesday.